Prescriptions of Eisai’s Aricept To New Patients Below 50%
This article was originally published in PharmAsia News
According to research carried out by the Japan Medical Information Research Institute, the share of new patients being prescribed Eisai’s Alzheimer drug Aricept in August 2012 decreased to just 45% due to the increase in generic drugs and the end of limits to long-term prescriptions.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.